PCVX vs. RVMD: Vaxcyte vs. Revolution Medicines Stock Comparison
How do Vaxcyte (PCVX) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Vaxcyte (PCVX) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | PCVX | RVMD |
|---|---|---|
| Name | Vaxcyte Inc. | Revolution Medicines, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.11 billion USD | 41.59 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 12, 2020 | February 13, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Total Return (1Y) | 59.00% | 224.80% |
| Total Return (3Y, Annualized) | 11.29% | 114.71% |
| Total Return (5Y, Annualized) | 21.60% | 43.47% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Volatility (1Y, Annualized) | 56.01% | 68.29% |
| Beta (5Y) | 1.26 | 1.42 |
| Max Drawdown (5Y) | -76.22% | -55.71% |
| Avg. Volume (3M) | 2.12M | 2.06M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Sharpe Ratio (1Y) | 0.98 | 3.23 |
| Sortino Ratio (1Y) | 1.76 | 6.92 |
Profitability
ROE (TTM)
Both Vaxcyte (PCVX) at -42.68% and Revolution Medicines (RVMD) at -93.56% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-42.68%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- PCVX
- -42.68%
- Q1
- -64.05%
- Min
- -167.77%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-93.56%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- RVMD
- -93.56%
- Min
- -167.77%
Net Margin (TTM)
Both Vaxcyte (PCVX) at 0.00% and Revolution Medicines (RVMD) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- RVMD
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-188.88%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- RVMD
- -188.88%
- Min
- -207.40%
Profitability Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| ROE (TTM) | -42.68% | -93.56% |
| ROA (TTM) | -24.98% | -32.13% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | -188.88% |
| Gross Margin (TTM) | 0.00% | 0.00% |
Growth
Revenue Growth
Neither Vaxcyte (PCVX) nor Revolution Medicines (RVMD) reports a revenue growth value for this period, so a direct comparison isn't possible.
EPS Growth
Neither Vaxcyte (PCVX) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Revenue Growth (YoY) | -- | -- |
| Revenue Growth (3Y CAGR) | -- | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Vaxcyte (PCVX) at 4.56 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.56
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- PCVX
- 4.56
- Q1
- 2.47
- Min
- 0.10
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.36
- Max
- 25.13
- Q3
- 12.13
- RVMD
- 8.36
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Vaxcyte (PCVX) at 0.09 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- PCVX
- 0.09
- Q1
- 0.02
- Min
- 0.00
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.50
- Max
- 1.42
- Q3
- 0.65
- RVMD
- 0.50
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Current Ratio (MRQ) | 4.56 | 8.36 |
| Debt / Equity (MRQ) | 0.09 | 0.50 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Vaxcyte (PCVX) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Vaxcyte (PCVX) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Vaxcyte (PCVX) nor Revolution Medicines (RVMD) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- PCVX
- --
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RVMD
- --
P/S Ratio (TTM)
A sales-based read is only available for Revolution Medicines (RVMD), whose P/S ratio of 210.51 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- PCVX
- --
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
210.51
- RVMD
- 210.51
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.83
- Max
- 13.53
- Q3
- 6.54
- PCVX
- 3.83
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.31
- RVMD
- 17.31
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | PCVX | RVMD |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | -- | 210.51 |
| P/B Ratio (MRQ) | 3.83 | 17.31 |
| Free Cash Flow Yield (TTM) | -5.24% | -2.13% |